RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Issue 1 (16th October 2020)

• Record Type: Journal Article
• Authors: Parker Kerrigan, Brittany C; Ledbetter, Daniel; Kronowitz, Matthew; Phillips, Lynette; Gumin, Joy; Hossain, Anwar; Yang, Jing; Mendt, Mayela; Singh, Sanjay; Cogdell, David; Ene, Chibawanye; Shpall, Elizabeth; Lang, Frederick F
• Is Part Of: Neuro-oncology advances. Volume 2:Issue 1(2020)
• Publication Date: 2020-10-16
• Subjects: FGFR3-TACC3 -- fusion genes -- glioblastoma -- precision medicine -- RNAi; 616.99481
• DOI: 10.1093/noajnl/vdaa132
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Fusion genes form as a result of abnormal chromosomal rearrangements linking previously separate genes into one transcript. The FGFR3-TACC3 fusion gene (F3-T3) has been shown to drive gliomagenesis in glioblastoma (GBM), a cancer that is notoriously resistant to therapy. However, successful targeting of F3-T3 via small molecular inhibitors has not revealed robust therapeutic responses, and specific targeting of F3-T3 has not been achieved heretofore. Here, we demonstrate that depleting F3-T3 using custom siRNA to the fusion breakpoint junction results in successful inhibition of F3-T3+ GBMs, and that exosomes can successfully deliver these siRNAs. Methods: We engineered 10 unique siRNAs (iF3T3) that specifically spanned the most common F3-T3 breakpoint with varying degrees of overlap, and assayed depletion by qPCR and immunoblotting. Cell viability assays were performed. Mesenchymal stem cell–derived exosomes (UC-MSC) were electroporated with iF3T3, added to cells, and F3-T3 depletion measured by qPCR. Results: We verified that depleting F3-T3 using shRNA to FGFR3 resulted in decreased cell viability and improved survival in glioma-bearing mice. We then demonstrated that 7/10 iF3T3 depleted F3-T3, and importantly, did not affect levels of wild-type (WT) FGFR3 or TACC3. iF3T3 decreased cell viability in both F3T3+ GBM and bladder cancer cell lines. UC-MSC exosomes successfully delivered iF3T3 in vitro, resulting in F3-T3 depletion. Conclusion: Targeting F3-T3 using siRNAs specific to the fusion breakpoint is capable of eradicating F3T3+ cancers without toxicity related to inhibition of WT FGFR3 or TACC3, and UC-MSC exosomes may be a plausible vehicle to deliver iF3T3.